Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Company Overview - Exelixis is a commercial stage biotech company focused exclusively on oncology [3] - The main value driver for the company is cabozantinib, marketed as COMETRIQ, which is the leading drug for renal cell carcinoma (RCC) [3] - The company has demonstrated strong commercial performance over the past several years in the kidney cancer space [3]